3P Learning Limited logo

3P Learning Limited (3PL)

Market Open
ASX ASX
171.93M Market Cap
- P/E Ratio
0% Div Yield
656 Volume
0 Eps
Want to track 3PL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 62 days

Summary

3PL trading today higher, an increase of 0% from yesterday's close, completing a monthly increase of 1.64%. Over the past 12 months, 3PL stock lost -26.19%.
3PL pays dividends to its shareholders, with the most recent payment made on Oct 22, 2015. The next estimated payment will be in 22 Oct 2015 on Oct 22, 2015 for a total of A$0.018.
The last earnings report, released on Aug 28, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 15, 2026.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on ASX (AUD).

3P Learning Limited (3PL) FAQ

On which exchange is it traded?

3P Learning Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is 3PL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 171.93M.

When is the next earnings date?

The next earnings report will release on Feb 15, 2026.

Has 3P Learning Limited ever had a stock split?

No, there has never been a stock split.

3P Learning Limited Profile

Diversified Consumer Services Industry
Consumer Discretionary Sector
Mr. Matthew Blake Sandblom CEO
ASX Exchange
AU0000003PL9 ISIN
AU Country
350 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

InnoCan Pharma Corporation is a pioneering pharmaceutical technology company with a keen focus on developing innovative drug delivery platforms that merge cannabidiol (CBD) with other pharmaceutical ingredients. The company's operations span across the United States, Canada, Europe, and other international markets. It is structured into two main segments: Pharmaceuticals and Consumer Wellness. At its core, InnoCan Pharma is committed to advancing the research and development of CBD loaded exosomes and the LPT CBD-loaded liposome platform. These platforms are designed to ensure precise dosing and the sustained, controlled release of CBD into the bloodstream, targeting conditions such as epilepsy and pain management. Established in 2018 and based in Calgary, Canada, InnoCan Pharma is at the forefront of integrating CBD into pharmaceutical and topical treatment products, aiming to bridge the gap between the health benefits of CBD and the needs of patients worldwide.

Products and Services

  • CBD loaded exosomes - This innovative research and development project focuses on utilizing exosomes (cell-derived nanoparticles) as a delivery system for cannabidiol (CBD). The aim is to target specific diseases with precision, enhancing the therapeutic effects of CBD.
  • LPT CBD-loaded liposome platform - A sophisticated drug delivery platform that encapsulates CBD in liposomes. This technology facilitates accurate dosing and ensures a prolonged and controlled release of CBD into the bloodstream. It is primarily developed for use in managing conditions like epilepsy and chronic pain.
  • Branded CBD integrated pharmaceutical and topical treatment products - InnoCan Pharma is actively involved in the commercialization and sale of branded pharmaceutical and topical treatments that integrate CBD. These products are designed to meet the needs of patients seeking reliable, CBD-based therapies.
  • Self-care products for a healthier lifestyle - Beyond its pharmaceutical technology focus, InnoCan also develops and markets a range of self-care products. These offerings aim to promote a healthier lifestyle through the benefits of CBD and other wellness-focused ingredients.
  • Product Brand Names - The company markets its diverse product portfolio under several brand names, including Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On. Each brand caters to different aspects of health and wellness, leveraging the therapeutic potential of CBD.

Contact Information

Address: 655 Parramatta Road, Leichhardt, NSW, Australia, 2040
Phone: 61 1300 850 331